In this trial, 453 patients who had stage IV NSCLC with KRAS mutations (codon 12 or 13) and disease progression after two lines of therapy were randomized in a ratio of 3:2 into abemaciclib and erlotinib groups (including a platinum-based regimen). Here, KRAS is linked to non-small cell lung carcinoma.